Cytoki Pharma is a clinical-stage biotechnology company pioneering a new class of medicines that harness the innate biology of IL-22 to address metabolic diseases, including obesity and type 2 diabetes, and conditions characterized by epithelial injury, such as inflammatory bowel disease
Cytoki Pharma is a clinical-stage biotechnology company pioneering a new class of medicines that harness the innate biology of IL-22 to address metabolic diseases, including obesity and type 2 diabetes, and conditions characterized by epithelial injury, such as inflammatory bowel disease.